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Abstract 
Research involving children is necessary for the continued advancement of children’s health and welfare. 
However, paediatric research necessitates a compromise between advances in medical knowledge and the 
exposure of children to risk. A large number of ethical guidelines and texts of varying legal force exist in the 
field of clinical research and in particular related to paediatrics. Differences, tensions or outright 
contradictions among the provisions of these texts can generate confusion leading to the adoption of 
different ethical standards. In this context, the real challenge is to ensure that each child involved in a 
clinical trial in the EU territory may rely directly to the same principles and rights. Taking international 
human rights law as the essential framework and starting point for the development of universal ethical 
principles relevant for paediatric research is a way to guarantee the application of the principle of equality 
of treatment, based on the respect of fundamental rights. The implementation, at national and local level, of 
the European Ethical Recommendations, based on international human rights law, seems to be the next step 
to develop quality and ethically sound paediatric research.  
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INTRODUCTION 
The main objective of clinical research is to develop generalizable knowledge to improve health and/or 
increase understanding of human biology. Ethical requirements for clinical research aim at minimizing the 
possibility of exploitation by ensuring that research subjects are not merely used but are treated with respect 
while they contribute to the social good [1].   
Clinical research on children raises many scientific and ethical concerns [2]. With respect to paediatric 
population, there are significant deficits in the objective knowledge of quality and efficacy of current 
preventive measures, pharmacokinetics and pharmacodynamics of medications, appropriate dosage and 
application form for different age periods, and of the adequacy of deriving children’s doses from adult 
studies [3].
 
The off-label or even off-licence use of medicine on children can have detrimental consequences 
in terms of unexpected adverse reactions and of access to the most up-to-date treatments.  
Recently, the need to stimulate paediatric research in Europe has resulted in regulatory measures to facilitate 
and support clinical trials in this field [4]. The call for more medical research involving children has also 
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raised the question whether the law as it stands strikes an appropriate balance between the need for clinical 
trials and the interests and rights of the child. While there is general agreement that children should be given 
special protection as research subjects, there are also concerns that too restrictive regulation may hinder 
research serving their long term health interests [5].  
Article 1 of the Universal Declaration of Human Rights expresses the basic right of all human beings to be 
free and equal in dignity and rights
 
[6]. The main ethical and legal imperative of all paediatric activities is to 
do everything “in the best interests of children”[7] . The United Nations Convention on the Rights of the 
Child [7] asserts that children have the right to say what they think should happen when adults make 
decisions that affect them and to have their opinions taken into account (article 12), have the right to get and 
share information (article 13), have the right to think and believe what they want  and practice their religion 
as long as they do not stop other people enjoying their rights (article 14) and have the right to privacy (article 
16). All these assume growing levels of capacity to consent, which have to be taken seriously. As children 
develop, it should be the degree of their maturity which determines when they are regarded as fully 
competent and capable of autonomous decisions. This will vary child to child.   
Apart from the general requirements of research on human subjects such as an adequate informed consent, a 
balance between risks and benefits, additional rules and principles have been developed at international and 
European level in order to protect the best interests of the children involved in clinical research. Furthermore, 
relevant guidelines can be derived from the UN Declaration on the rights of the child, whereupon every child 
has the fundamental right to life and dignity, and is entitled to optimal care, based on the scientific evaluation 
of preventive, diagnostic and therapeutic measures. Paediatric care includes the responsibility to achieve the 
highest level of knowledge, consideration of the child-specific somatic, mental and social development, 
emphatic and trustworthy communication with the child and parents [8].
 
 
In this article we will describe the methodology of “ethical reasoning” that finally led TEDDYNoE (Task-
force in Europe for Drug Development for the Young - Network of Excellence) to propose, during the 
consultation process [9], the integration of international human rights law in the “European Ethical 
Recommendations on clinical trials involving minors”, finally approved by the European Commission in 
2008 [10].
 
 This document aims at facilitating the conduct of paediatric clinical trials in the EU and at 
contributing to the protection of children involved. 
METHODOLOGY 
Ethical principles and guidelines  
According to the main international declarations and guidelines [11, 12, 13, 14, 15], all research involving 
human subjects should be conducted in accordance with three basic ethical principles, namely respect for 
persons, beneficence and justice.  
Respect for persons incorporates at least two fundamental ethical considerations: a) respect for autonomy, 
which requires that those who are capable of deliberation about their personal choices should be treated with 
respect for their capacity for self-determination; and b) protection of persons with impaired or diminished 
autonomy, which requires that those who are dependent or vulnerable be afforded security against harm or 
abuse.  
 “Vulnerability” refers to a substantial incapacity to protect one’s own interests owing to such impediments 
as lack of capability to give informed consent, lack of alternative means of obtaining medical care or other 
expensive necessities, or being a junior or subordinate member of a hierarchical group. Accordingly, special 
provision must be made for the protection of the rights and welfare of vulnerable persons, as minors [16].  
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Beneficence refers to the ethical obligation to maximize benefits and to minimize harms. This principle gives 
rise to norms requiring that the risks of research be reasonable in the light of the expected benefits, that the 
research design be sound, and that the investigators be competent both to conduct the research and to 
safeguard the welfare of the research subjects. Justice refers to the ethical obligation to treat each person in 
accordance with what is morally right and proper. In the field of research the principle refers primarily to 
distributive justice, which requires the equitable distribution of both the burdens and the benefits of 
participation in research. 
 
In the light of these principles, consensus is emerging concerning what elements are necessary requirements 
for the ethical conduct of clinical research. These include: scientific value and validity, favorable risk-benefit 
ratio, fair subject selection, informed consent, independent review and respect of subjects [17]. 
So, to be ethical, clinical research must be valuable, meaning that it evaluates a diagnostic or therapeutic 
intervention that could lead to improvements in health or well-being; or tests a hypothesis that can generate 
important knowledge about structure or function of human biological systems, even if that knowledge does 
not have immediate practical ramifications [17, 18]. 
A valuable research must be conducted in a methodologically rigorous manner. The methods must be valid 
and practically feasible: the research must have a clear scientific objective; it has to be designed using 
acceptable principles, methods and reliable practices; it has sufficient power to definitively test the objective 
and offer a plausible data analysis plan. In addition, it must be possible to execute the proposed study 
[17,18]. Paediatric research design should employ wherever possible child-friendly settings, personnel and 
procedures that limit invasiveness to a meaningful minimum [19]. 
 
Scientific goals of the study have to be the primary basis for determining the groups and individuals that will 
be recruited and enrolled, both through the development of a strategy and specific inclusion and exclusion 
criteria that, in case of paediatric research, explicitly recognize the vulnerability of children [20]. 
Clinical research can be justified only if, in accordance with the scientific aims of the study and the relevant 
standards of clinical practice, the potential risks to individual subjects are firstly identified and minimized. 
To this aim, procedures which are consistent with sound research design and which do not necessarily 
expose subjects to risk should be used, and whenever appropriate, procedures already being performed on the 
subjects for diagnostic or treatment purposes should be adopted [18]. Secondly, the health-related potential 
benefits of the research to individual subjects are to be delineated and enhanced.  Finally, the potential 
benefits to individual subjects and society have to proportionate to or outweigh the risks.  
In the evaluation of the expected impact on an individual patient or a group of a proposed research, benefits 
can be of several kinds: advancing the patient’s or society’s interests, producing new knowledge of value to 
future patients or devising a policy which advances the common good. Risks are the estimates of 
probabilities or possibilities of injuring a patient or a group, for example producing harms that violate the 
interests of the research subjects. Harms may be financial, physical, emotional or spiritual, singly or in 
combination [20].  
 
When dealing with paediatric research it is necessary to be more risk averse and seek evidence of direct 
personal benefits or benefits to their own class of persons as a result of research participation. Benefits 
should be evaluated conservatively, whereas harms are assessed more broadly [21]. Benefits must be 
apparent to the individual child or to children in general or the research cannot be pursued even if involving 
minimal risk. Harms must be assessed from the perspective of the child and be sensitive to the child’s lesser 
capacity to understand what is going on, the effects of disruptions, inconvenience and novel situations on the 
child and family [21]. 
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The threshold for harm in children uses the standard of “minimal risk” and “minimal burden” beyond which 
specific justification for such risk/burden exposure must be present. The research bears a minimal risk if, 
having regard to the nature and scale of the intervention, it is to be expected that it will result, at the most, in 
a very slight and temporary negative impact on the health of the person concerned. It bears a minimal burden 
if it is to be expected that the discomfort will be, at the most, temporary and very slight for the person 
concerned. In assessing the burden for an individual, a person enjoying the special confidence of the person 
concerned shall assess the burden where appropriate [22].  
 
Nobody should be forced to engage in activities inconsistent with his or her own values, interests and 
preferences. Freely given informed consent is the foundation stone of contemporary ethics of clinical 
research. It can be withdrawn at any moment without any prejudice, liability or discrimination against the 
participants in the research. Consent requires that the individual be competent. Due to developmental and 
cognitive limitations, children are not yet competent persons, meaning that they are not capable of providing 
legal consent to research participation [23].
 
 
In the absence of the capacity to provide consent, permission for research participation must be sought from 
a proxy, taking into account the best interests of the child [24, 26]. Legal representatives have to put 
foremost choices that preserve well-being and maintain the capacity of the child to ultimately develop into 
autonomous decision-maker [25]. Child’s assent or dissent has to be considered as a lower level of decision-
making capability that is developmentally determined. The research should not start or be discontinued if the 
child raises objections or resistance. Children must be solicited in an appropriate manner sensitive to their 
current cognitive and developmental abilities. Well-crafted age appropriate informational materials should 
aid investigators in explaining to potential child research participants exactly which elements of their 
medical care are research, and therefore optional [27, 28]. 
 
Another essential requirements for ethical conduct of research is the independent review of clinical protocols 
by an Ethics committee. This provides a mechanism for third-party validation separate from the vested 
interests of investigators that ensures that scientific and ethical standard are being met. It is a means of 
keeping in check potential conflicts of interests, protecting the welfare of subjects, allowing for transparency 
and finally providing public (i.e. social) accountability that is reassuring to potential subjects [21].  
To guarantee the well-being and rights of children participating in a clinical research, protocols have to be 
endorsed by an Ethics committee with paediatric expertise or after taking advice in clinical, ethical and 
psychological problems in the field of paediatrics [29].  
 
Finally, providing participants in clinical research additional information about the effect of the intervention 
or the subject’s clinical condition learned from the research, protecting confidentiality and monitoring well-
being are key aspects of an ethical research to guarantee the respect for persons and their autonomy, in the 
light of the principles of beneficence and non-maleficence. 
Legal framework 
At European level, Oviedo Convention [34] and Clinical trial Directive 2001/20/EC [29] establish that the 
accepted basis for the conduct of clinical trials in humans is founded on the protection of human rights 
(namely the right to life, to physical and mental integrity and to privacy) as well as human dignity, that is 
“the cardinal principle of the legal norms relating to bioethics” [30].   
As a direct corollary of the human dignity, these documents affirm the primacy of the human being over 
science and society and emphasize two fundamental ideas: first, that science is not an end in itself but only a 
5 
 
means for improving the welfare of individuals and society; second, that people should not be reduced to 
mere instruments for the benefit of science.  
Besides, through the incorporation of the ICH Guidance on Good Clinical Practice and its effective adoption 
as binding law, Directive can be seen as affording protection to individual research participants, and 
especially to vulnerable subjects (e.g. children). To this aim, Directive 2001/20/EC devotes a specific article 
(art. 4) to minors’ protection. 
 
Nevertheless, even if all the European countries implemented Directive 2001/20/EC, with respect to clinical 
research practices in paediatrics, it exists a “regulatory gap” or rather a “regulatory conflict” not only among 
ethical and legal frameworks at European level but, most of all, between the European ethical/legal 
frameworks (Directive 2001/20/EC, Oviedo Convention, Additional Protocol on Biomedical research, etc.) 
and national regulations [31]. 
Many differences exist in Europe related to the guarantees of children rights, to the protection of minors 
involved in clinical trials across Europe as well as to the ethical reviewing of paediatric protocols [32, 33].  
Some countries go beyond the requirements of the Directive: for instance they assure more importance to the 
will of the minors (Spain) or consider their will necessary to involve them in clinical trials (Denmark, 
Estonia and the Netherlands). The expression of will is accepted at different age limits (12 years in Spain, 
15-17 years in Denmark, 7-17 years in Estonia, 12 years in The Netherlands) [31, 32]. 
With reference to acceptable risk and burden for children involved in clinical research, Greece, Ireland, Italy, 
and Belgium would seem to follow the more liberal Directive (requiring “minimising” risk and burden, also 
if there is only group benefit). The Netherlands, France and Finland seem to follow the stricter Additional 
Protocol on Biomedical research [22], that requires minimal risk and burden if there is only group benefit 
[33, 46-50]. 
 
Furthermore, the wide range of situations due to a no-coordinate Directive 2001/20/EC implementation, the 
great differences in cultural and economic environment, the large number of texts of varying legal force 
existing in the field of clinical research, with special reference to paediatrics, can cause difficulties in 
imposing penalties on researches that violate human rights of minors in the name of medical research. In this 
context, it was imperative to have a systematic and coherent framework for evaluating clinical studies that 
incorporates all relevant ethical considerations. 
 
International Human Rights Law and European Ethical recommendations 
In 2008, the ad hoc group for the development of implementing guidelines for Directive 2001/20/EC, chaired 
by the European Commission, approved the document “Ethical Considerations for Clinical Trials on 
Medicinal Products with the Paediatric Population”[10]. According with proposals submitted by 
TEDDYNoE during consultation process [9], these recommendations integrate principles contained in all the 
international/European ethical/legal sources relevant for biomedical research and consistent with the 
international human rights law [6,7, 11-16, 22, 29, 34-41]. 
The purpose was to ensure that each minor involved in a clinical trial in the EU territory may rely directly to 
the same principles and rights in order to apply the principle of equality of treatment that is an implicit 
milestone in building a European wide-democratic society, based on the respect of fundamental rights.  
 
 “The human rights framework” provides a more useful approach for analyzing and responding to modern 
public health challenges that any framework thus far available within the biomedical tradition” [42]. Since 
the adoption of the Universal Declaration of Human Rights in 1948, a large number of international 
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instruments have been adopted to ensure the unconditional respect for the human person in very diverse 
contexts. Furthermore, the existing human rights system, with its extensive body of international standards 
and wide range of follow-up mechanisms, represents one of the most remarkable achievements of our time. 
Therefore, it is important to make use of this rich normative and institutional set-up in order to protect people 
from harm in the field of biomedicine [52]. 
All the above mentioned  sources [6,7, 11-16, 22, 29, 34-41] address ethical issues related to medicine, life 
sciences and associated technologies as applied to children, taking into account their social, legal and 
environmental dimensions, as well as the necessity to protect individuals and groups of special vulnerability 
(as children) and to respect the personal integrity of such individuals.  
Since the respect of fundamental rights constitutes, in value systems recognized in Europe, an indivisible 
obligation for the public authority to fulfill, the methodological approach aimed at integrating human rights 
law seemed to be particularly useful to recognize the importance of freedom of research and the benefits 
derived from scientific and technological developments, while providing a universal framework of principles 
and procedures to guide EU and States in the formulation of their legislation, policies or other instruments in 
the field of bioethics and paediatric clinical research.  
 
The methodology of using international human rights ethical reasoning in developing a European ethical 
framework for paediatric research is based on the awareness of interrelation and complementarity of the 
principles contained in all the ethical/legal European/international sources as well as of the pluralistic and 
non-hierarchical relationship existing between these principles. The extent to which principles referred to in 
various documents (both legal and ethical instruments) are taken into account in national or regional 
legislation within EU is variable. They overlap in many areas, but some give greater precision on certain 
points whilst on others there are differences in approach. 
In case of tensions or outright contradictions among the provisions of the various guidelines related to 
clinical research [43], conflicts should be solved by finding a balance between competing principles, taking 
into account the “highest-ethical standards” (as standards providing with more guarantees) with the aim to 
protect health and rights of the child. The legal value of the source or a culturally sensitive interpretation of 
the principle shall be considered as well.  
In such a sensitive field as bioethics and clinical research, where socio-cultural, philosophical and religious 
traditions come into play, using human rights framework should facilitate the formulation of universal 
standards, because international human rights law is based on the assumption that some basic rights 
transcend cultural diversity.  
So, the mentioned methodology aimed at founding ethical reasoning on human rights provided European 
ethical recommendations with an opportunity to be accepted by different cultures and traditions, even outside 
Europe. European ethical Recommendations, expected to facilitate a coordinated approach to the application 
of the Clinical Trial Directive across the EU, with special reference to paediatric research, are also relevant 
to clinical trials conducted in non-EU countries especially developing countries. 
 
These Recommendations integrate the Clinical Trial Directive provisions and clarify the process of 
assessment of the benefit and risk balance, the process of information and consent/assent according to age 
groups and level of minors’ maturity and the process of ethical review of paediatric protocols. They also deal 
with individual data protection and insurance issues. The main principles are, first, that children may not be 
included in clinical trials if the same results can be obtained using adults. Second, whenever possible the 
research should have a direct benefit for the children involved; without such a benefit, the risks must be 
strictly limited and every effort must be made to reduce pain, discomfort and fear. Third, parents or 
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guardians must be fully informed and have given consent for the participation of their child; minors should 
be involved in the informed consent process in proportion to age and degree of maturity.  
In particular, with reference to consent/assent process, new EC recommendations specify that separate 
information sheets for adults and children, and separate consent and assent forms should be used in order to 
provide age appropriate information, in language and wording appropriate to age, psychological and 
intellectual maturity. Assent, like consent, is a continuous process and should be sought during the trial as 
well. The information process provided to the child and the child’s response should be documented. Every 
effort should be made to understand and respect differences of opinion between the child and his/her parents 
or legal representative. Strong and definitive objections from the child should be respected. 
 
With reference to paediatric expertise to be included in the Ethics committee in charge of reviewing 
protocols, it is underlined that this expertise goes beyond having dealt with children and could be defined on 
the basis of education and experience on the various aspects of child development, ethics and psychosocial 
aspects. Furthermore, qualifications and expertise of the experts used and the members of the Ethics 
Committee should be documented and annexed to its opinion.  
Finally, ethical standards, principles and requirements contained in the European Ethical Recommendations 
could be reinterpreted, refined and revised with changes in science and experience. Nevertheless, being 
human rights the standard-setter in bioethics, according to the art. 27 of the Universal Declaration on 
Bioethics and Human Rights, any limitation on the application of these principles needs to be consistent with 
the international human rights law [37]. 
Conclusions 
The ethical conduct of clinical research in children is challenged by the inherent vulnerability of this 
population. Children should enjoy the benefits of clinical research but they should be protected from harms 
to their health and well-being. Even if these two objectives seem to be partly incompatible [2, 51],
 
it is 
important to balance them in order to meet the specific therapeutic needs of the paediatric population, 
without subjecting this population to unnecessary trials. Thus, trials involving children are on trial [44].  
The European Paediatric Regulation provides rewards, incentives and obligations for pharmaceutical 
companies to facilitate the development and availability of high-quality medicines for children. Meanwhile, 
high ethical standards, the education and training of investigators in good clinical practice as well as the 
protection of health and rights of children involved in clinical trials are needed. The ethical obligation to 
assess interventions in children should override drug profitability projections [44].  
Thus, the real challenge is to translate ethical principles into clinical research and to establish procedures that 
are consistent with human rights international law, both ethically sound and culturally sensitive, although 
there may be times when these two requirements appear to be in conflict.  
In this context, the European Ethical Recommendations, providing an ethical framework based on 
international human rights law, leads to explicit heightened universal standards of ethical propriety that seek 
to balance the real need to conduct research and the need to protect children from the exploitation of their 
vulnerability.  
It is our collective responsibility to promote the application of these updated rules. To this aim efforts are 
needed at both regulatory and scientific levels to implement these ethical standards at national and local 
level. It shall be also essential to increase the awareness of the ethical aspects of paediatric research and to 
promote public debates, education and training initiatives involving main stakeholders (e.g. sponsors, 
investigators, ethics committees, regulatory bodies, patients associations). 
This methodological approach is crucial in the perspective of the internationalization of research that creates 
new responsibilities, particularly regarding research carried out in developing countries under the scientific 
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and financial control of developed nations. To develop sound ethical principles intertwined with international 
human rights law and facilitate their implementation globally would contribute to the development of 
research of high quality that respects the fundamental rights of each individual and is a source of progress for 
the health and welfare of everyone across the globe.  
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